Weight Loss Centre

There is no single "best" named diet. Meta-analyses and year-long trials show similar weight loss across low-carb and low-fat approaches when calories and adherence are matched. Pick a pattern you can sustain, built on Kenya's food-based guidelines: plenty of vegetables, legumes, lean proteins, whole grains, and minimal ultra-processed foods.

For the largest and most durable results, bariatric surgery outperforms medicines and lifestyle alone in long-term studies, with ~20–30% total body-weight loss at 5–10 years in typical procedures. GLP-1 medicines like semaglutide average ~15% at 68–104 weeks when taken continuously with lifestyle support. Choice depends on health status, BMI, and goals.

Yes, but by prescription and primarily for type 2 diabetes. Kenya's Pharmacy and Poisons Board has warned about falsified Ozempic pens and misuse for cosmetic weight loss. Obtain it only through a licensed clinician and pharmacy, and avoid online or informal sources.

Rapid losses of this size are unsafe and mostly reflect water loss, not true fat loss. Evidence-based guidance targets about 0.5–1 kg per week using a sustainable calorie deficit, activity, sleep, and stress control. If you need faster medical support, seek supervised care rather than extreme diets.

On social media, "3×3" typically means hitting three simple goals before midday, such as 3,000 steps, about one-third of daily water, and ~30 g of protein. It can be a helpful habit cue, but it is not a validated clinical protocol. Use it only if it supports the fundamentals of calorie balance, quality diet, movement, sleep, and stress control.

That pace exceeds safe medical recommendations. Most authorities advise about 0.5 to 1 kg per week through a moderate calorie deficit and behavior change. If you have significant obesity or complications, discuss medical options such as GLP-1 therapy or surgery rather than attempting crash diets.

Results vary with dose titration and lifestyle. Real-world and trial data suggest roughly 6% body-weight loss at 3 months and about 11% at 6 months on semaglutide with lifestyle changes, which averages around 2% to 4% per month early on. Clinicians adjust dose for tolerance and safety.

Seventeen kilos in 12 weeks is beyond typical safe targets. Evidence supports gradual loss with lifestyle, or consider structured medical pathways: GLP-1 therapy (≈10–15% at 6–12 months) or bariatric surgery for larger, sustained reductions when indicated. A supervised plan is essential.